Japan's Chuikyo settles on 5.1% new drug development premium and 2.2% price cut
At its general assembly last month, Japan's Chuikyo (the Central Social Insurance Medical Council) revealed that the premium for the development of new drugs is to be set at 5.10%, slightly below the 5.13% announced-previously by the Korosho (Ministry of Health, Labor and Welfare), which will be introduced on a trial basis from this April.
Chuikyo members also approved revisions to the proposed fiscal year 2010 drug price system reform that they had cleared on December 22 last year. This means that the premium rate will be 80% of what they had proposed and the across-the-board price cut for long-listed drugs - to be introduced in April - will be 2.2%, rather than 2.0%, reported Pharma Japan.
Majority of drugmakers welcome new pricing system
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze